QNTMNasdaq

Quantum Biopharma Ltd.

Healthcare·Oncology·Phase 2·Toronto, ON, Canada
OncologyPainDermatologyMusculoskeletal

Quantum Biopharma Ltd. (QNTM): 1 pipeline candidate · ~32 mo cash runway · 10 clinical trials. Updated within the last hour.

6.2/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway8.9

32.2 months

Financial Health6.4

D/E 1.19

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Quantum Biopharma Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$25.9M

Cash

$1.9M

Quarterly Burn

$306K

Runway

32.2 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Feb 2029
Today~35 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
fsd201Phase 2

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

20

Total value held

$865K

HolderSharesValue
advisorshares investments llc108,591$524K
jane street group, llc31,501$152K
citadel advisors llc15,863$77K
marex group plc13,468$65K
osaic holdings, inc.6,375$31K
atlantic union bankshares corp1,000$5K
farther finance advisors, llc1,000$4K
jones financial companies lllp700$3K
cetera trust company, n.a250$1K
wells fargo & company/mn100$477

Showing top 10 of 20 institutional holders of Quantum Biopharma Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

10 clinical trials·CEO: Mr. Zeeshan Saeed

Frequently asked questions

How many drug candidates are in Quantum Biopharma Ltd.'s pipeline?

Quantum Biopharma Ltd. (QNTM) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is Quantum Biopharma Ltd.'s lead drug candidate?

Quantum Biopharma Ltd.'s most advanced tracked candidate is fsd201 (Phase 2) for Mast Cell Activation Syndrome.

What is Quantum Biopharma Ltd.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Quantum Biopharma Ltd. has approximately 32.2 months of cash runway.

What is Quantum Biopharma Ltd.'s market capitalization?

Quantum Biopharma Ltd.'s market capitalization is approximately $25.9M.

Who is the CEO of Quantum Biopharma Ltd.?

Mr. Zeeshan Saeed is the chief executive officer of Quantum Biopharma Ltd. (QNTM).

Get the full picture on Quantum Biopharma Ltd.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.